NeoGenomics, Inc. Class Action Lawsuit - NEO

(1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

In order to be eligible to join the NEO class action lawsuit, you must have incurred a loss on shares of NeoGenomics purchased during the class period listed above.

If you suffered a loss in NeoGenomics during the relevant time frame or pursuant to the relevant offering(s), you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.